A few months ago, I wrote a column on the rapid advancements in human genome technology and how Wall Street was treating those advances like a luckless poker player treats a pair of aces on the deal and two more on the flop. In other words, very enthusiastically. It turns out that genomics is only half the story. In Wall Street brokerage firms, in financial advisor circles, and on mutual fund trading desks, the other shoe has dropped in the form of the biochip — those DNA-styled microchips that more and more industry companies are starting to use to examine the genomic templates of various diseases (and hopefully to help them find ways to cure them). In laymen's terms, biochips are sliver-sized microarray disks that harbor tens of thousands of DNA segments (or "probes" as laboratories call them) that represent human genes.

Biochips are creating a great deal of interest in biopharmaceutical and investment circles. What can new chip technology offer investors? Apparently plenty.

According to a research paper on DNA chip technology released by the Swiss pharmaceutical firm Roche, individual DNA chips can provide "actionable information relevant for research, diagnosis, and treatment and open the door to more individualized medicine. The function of genes or predispositions for certain tumor diseases can be diagnosed, as can the tolerability of drugs. This facilitates the selection and dosage of active ingredients for treatment. In addition, unnecessary costs in the healthcare sector can be avoided."

But it ' s not all about disease treatment and prevention. Other biochip uses include handheld devices for testing microbes in food and DNA fingerprinting. The threat of bioterrorism and biowarfare are natural venues for biochip exploration. The chips can help researchers detect biological and chemical warfare agents much faster and more accurately than conventional laboratory analysis.

A HARMONIC CONVERGENCE? Biochips were first developed in the late 1980s by Santa Clara, CA-based Affymetrix and have picked up steam, developmentally at least, in the last two or three years from Amersham, Agilent Technologies, Illumina, and Applied Biosystems. Firms like Genomic Solutions, Caliper, and Ciphergen all have large-scale DNA-chip projects underway, while other companies like Clinical Micro Sensors, ACLARA BioSciences, and Phylos have launched smaller-scale biochip campaigns.

The market for biochips, both near- and long-term, is potentially huge. According to a 2002 report by the consulting firm BioPerspectives, the protein biochip market will reach $700 million in sales by 2006.

"Though they get cheaper every year, just like their cousins in computers and electronics, (biochip industry) dollar-sales figures continue to rise — as much as 50% in 2003, to perhaps $500 million," Aaron Geist, an analyst at Robert W. Baird in Milwaukee, told Business Week.

According to Research and Markets, a leading source for international market research, the protein biochip market is underserved, despite growing from $70 million in 2001 to $100 million in 2002. Its Protein Biochips 2003 Report presents a detailed market model and thorough analysis of the technologies and business strategies of 38 leading protein biochip companies. Protein Biochips 2003 projects that the market will grow to more than $400 million in 2007, a compound annual growth rate of more than 35%

What does all this growth mean to the bean counters and stock pickers on Wall Street?

In a macro-sense, it means a great deal. Financial analysts have come to know and love the semi-conductor industry, making chip firms like Intel and Micro Devices Big Board favorites over the past 20 years. Investment types have also fallen head over heels for biosciences companies, where the thought process on Wall Street is that biopharmaceuticals is where you'll find the next big thing.